Singapore: Pfizer has completed the sale of its nutrition business to Nestlé for $11.85 billion in cash, following the conclusion of the required regulatory process in most markets. In certain countries where completion will be delayed due to ongoing regulatory review, Pfizer will continue to operate the business on an interim basis.

"The completion of the sale of the nutrition business to Nestlé demonstrates our commitment to maximizing the value of our businesses and prudently managing capital," stated Mr Frank D'Amelio, chief financial officer, Pfizer.

"We remain focused on enhancing shareholder value, and our new $10 billion share repurchase program is now effective upon the completion of the sale and will be utilized over time," Mr D'Amelio added.